Literature DB >> 34600033

Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration's September 1, 2021, data safety communication.

Morgan Murphrey1, Reid Alexander Waldman2, Timothy Durso3, Jane M Grant-Kels4.   

Abstract

Entities:  

Keywords:  Janus kinase inhibitor; abrocitinib; alopecia areata; atopic dermatitis; baricitinib; psoriasis; ruxolitinib; tofacitinib; upadacitinib

Mesh：

Substances：

Year:  2021        PMID： 34600033     DOI： 10.1016/j.jaad.2021.09.051

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   15.487


× No keyword cloud information.
  3 in total

Review 1.  Immunopathology and Immunotherapy of Inflammatory Skin Diseases.

Authors:  Ahreum Song; Sang Eun Lee; Jong Hoon Kim
Journal:  Immune Netw       Date:  2022-02-14       Impact factor: 5.851

Review 2.  Safety and Danger Considerations of Novel Treatments for Atopic Dermatitis in Context of Primary Cutaneous Lymphomas.

Authors:  Karol Kołkowski; Magdalena Trzeciak; Małgorzata Sokołowska-Wojdyło
Journal:  Int J Mol Sci       Date:  2021-12-13       Impact factor: 5.923

3.  Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report.

Authors:  Mariateresa Cantelli; Fabrizio Martora; Cataldo Patruno; Paola Nappa; Gabriella Fabbrocini; Maddalena Napolitano
Journal:  Dermatol Ther       Date:  2022-02-10       Impact factor: 3.858
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.